Based on our observation we think that it would be important to test combined AR- and NF-κB inhibition, probably including PI3K inhibitors, in preclinical prostate cancer models, and at a later stage also in clinical studies of metastasizing prostate cancer. The gene discussed is NFKB1; the disease is prostate carcinoma.